In this podcast, Saad Z. Usmani, MD, MBA, speaks about the efficacy of daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma and impaired renal function from the phase 3 Maia Study based on Lenalidomide starting dose. He also presented on this topic at the 63rd ASH Annual Meeting & Exposition.